---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-011256"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2022-01-18T23:59:59+00:00"
generated_at: "2026-06-27T17:25:15.049318+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics amends loan with Mayne Pharma: limit to $281K, maturity Dec 2022

## Summary
- Facility limit increased by $50,000 to $281,000; maturity extended to December 31, 2022.
- Additional $50,000 available for drawdown from Feb 1 to Mar 31, 2022, in minimum $25,000 increments.
- Original $231,000 fully drawn; proceeds used for working capital and deferred employee compensation.
- Loan amendment with majority stockholder Mayne Pharma; rest of Loan Agreement unchanged.

## SEC filing metadata
- accession: 0001193125-22-011256
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2022-01-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312522011256/0001193125-22-011256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312522011256/d284256d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-011256
- JSON: https://secwatch.observer/filing/0001193125-22-011256.json
- Plain text: https://secwatch.observer/filing/0001193125-22-011256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.